rs200483989
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000341.4(SLC3A1):c.808C>T(p.Arg270Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000186 in 1,613,664 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00018 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00019 ( 1 hom. )
Consequence
SLC3A1
NM_000341.4 stop_gained
NM_000341.4 stop_gained
Scores
2
4
1
Clinical Significance
Conservation
PhyloP100: 1.15
Genes affected
SLC3A1 (HGNC:11025): (solute carrier family 3 member 1) This gene encodes a type II membrane glycoprotein which is one of the components of the renal amino acid transporter which transports neutral and basic amino acids in the renal tubule and intestinal tract. Mutations and deletions in this gene are associated with cystinuria. Alternatively spliced transcript variants have been described, but their biological validity has not been determined. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 2-44286074-C-T is Pathogenic according to our data. Variant chr2-44286074-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 336195.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-44286074-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC3A1 | NM_000341.4 | c.808C>T | p.Arg270Ter | stop_gained | 4/10 | ENST00000260649.11 | NP_000332.2 | |
SLC3A1 | XM_011533047.4 | c.808C>T | p.Arg270Ter | stop_gained | 4/10 | XP_011531349.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC3A1 | ENST00000260649.11 | c.808C>T | p.Arg270Ter | stop_gained | 4/10 | 1 | NM_000341.4 | ENSP00000260649 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000178 AC: 27AN: 152062Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
27
AN:
152062
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000394 AC: 99AN: 251434Hom.: 0 AF XY: 0.000375 AC XY: 51AN XY: 135884
GnomAD3 exomes
AF:
AC:
99
AN:
251434
Hom.:
AF XY:
AC XY:
51
AN XY:
135884
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000187 AC: 273AN: 1461602Hom.: 1 Cov.: 31 AF XY: 0.000182 AC XY: 132AN XY: 727128
GnomAD4 exome
AF:
AC:
273
AN:
1461602
Hom.:
Cov.:
31
AF XY:
AC XY:
132
AN XY:
727128
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000178 AC: 27AN: 152062Hom.: 0 Cov.: 32 AF XY: 0.000215 AC XY: 16AN XY: 74266
GnomAD4 genome
AF:
AC:
27
AN:
152062
Hom.:
Cov.:
32
AF XY:
AC XY:
16
AN XY:
74266
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
3
ExAC
AF:
AC:
27
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:10
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cystinuria Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 16, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The SLC3A1 c.808C>T (p.Arg270Ter) variant has been reported in at least 11 individuals with cystinuria, including two siblings, in a homozygous state, and one individual in a compound heterozygous state (Pras et al. 1995; Endsley et al. 1997; Gitomet et al. 1998; Botzenhart et al. 2002; Chatzikyriakidou et al. 2005; Merieau et al. 2009). Four of the individuals homozygous for the p.Arg270Ter variant were of Ashkenazi Jewish ancestry (Pras et al. 1995). Control data are not available for the variant which is reported at a frequency of 0.00041 in the European (non-Finnish) population of the Exome Aggregation Consortium database. Based on the evidence and due to the potential impact of stop-gained variants, the p.Arg270Ter variant is classified as pathogenic for cystinuria. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 25, 2022 | - - |
Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_000341.3:c.808C>T in the SLC3A1 gene has an allele frequency of 0.009 in Ashkenazi Jewish subpopulation in the gnomAD database. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Botzenhart E et al. identified this variant in two patients with cystinuria, including one in homozygous state amd one in compound heterozygous state (R270X/M467T) (PMID: 12234283 ). Gitomer WL et al. found this mutation in 3 patients in homozygous status, two were siblings (PMID: 9768685). Taken together, we interprete this variant as Pathogenic/Likely pathogenic. ACMG/AMP Criteria applied: PVS1, PM3_Strong, PP4. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 27, 2023 | This sequence change creates a premature translational stop signal (p.Arg270*) in the SLC3A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC3A1 are known to be pathogenic (PMID: 24610330, 25109415, 25964309). This variant is present in population databases (rs200483989, gnomAD 0.8%). This premature translational stop signal has been observed in individuals with cystinuria (PMID: 7539209, 28646536). ClinVar contains an entry for this variant (Variation ID: 336195). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2023 | SLC3A1: PVS1, PM2 - |
SLC3A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 29, 2024 | The SLC3A1 c.808C>T variant is predicted to result in premature protein termination (p.Arg270*). This variant has been reported in the homozygous and compound heterozygous state in multiple individuals with autosomal recessive cystinuria (Pras et al. 1995. PubMed ID: 7539209; Endsley et al. 1997. PubMed ID: 9186880; Botzenhart et al. 2002. PubMed ID: 12234283; Chatzikyriakidou et al. 2005. PubMed ID: 16225397; Tostivint et al. 2017. PubMed ID: 28646536) and has been reported to co-segregate with disease in at least one family (Gitomer et al. 1998. PubMed ID: 9768685). This variant is reported in 0.88% of alleles in individuals of Ashkenazi Jewish descent in gnomAD and has been described as a possible founder variant (Pras et al. 1995. PubMed ID: 7539209). Nonsense variants in SLC3A1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Autism spectrum disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Gene Friend Way, National Innovation Center | Jul 28, 2023 | This sequence change creates a premature translational stop signal (p.Arg270*) in the SLC3A1 gene. It is expected to result in an absent or disrupted protein product which can manifest as kidney disease. In autism, there have been studies that show a link between ASD and kidney disease. PMID: 33340339. Mutations in SLC3A1 are known as the causative factor of cystinuria, which involving the defective transepithelial transport of cystine and the ability to reabsorb cystine into the blood (PMID: 25109415, 25964309). Meanwhile, plasma concentration of cystein is significantly decreased in ASD children (PMID: 15585776). In our study, an ASD patient carries this SLC3A1 rs200483989 mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A;A;A;A;A;D
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at